Revvity, Inc. (RVTY)
| Market Cap | 11.29B +0.3% |
| Revenue (ttm) | 2.90B +4.8% |
| Net Income | 239.68M -16.4% |
| EPS | 2.09 -10.9% |
| Shares Out | 111.80M |
| PE Ratio | 48.35 |
| Forward PE | 18.46 |
| Dividend | $0.28 (0.28%) |
| Ex-Dividend Date | Jul 17, 2026 |
| Volume | 2,441,920 |
| Open | 99.13 |
| Previous Close | 98.85 |
| Day's Range | 94.60 - 102.23 |
| 52-Week Range | 81.22 - 118.30 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 107.46 (+6.4%) |
| Earnings Date | May 5, 2026 |
About RVTY
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including... [Read more]
Financial Performance
In 2025, Revvity's revenue was $2.86 billion, an increase of 3.67% compared to the previous year's $2.76 billion. Earnings were $241.20 million, a decrease of -10.79%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price target is $107.46, which is an increase of 6.40% from the latest price.
News
Revvity price target raised to $105 from $95 at Barclays
Barclays raised the firm’s price target on Revvity (RVTY) to $105 from $95 and keeps an Equal Weight rating on the shares.
Revvity price target lowered to $117 from $125 at Baird
Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Revvity (RVTY) to $117 from $125 and keeps an Outperform rating on the shares. The firm updated its model
Revvity price target lowered to $100 from $110 at Stifel
Stifel lowered the firm’s price target on Revvity (RVTY) to $100 from $110 and keeps a Hold rating on the shares.
Revvity price target lowered to $90 from $96 at JPMorgan
JPMorgan analyst Casey Woodring lowered the firm’s price target on Revvity (RVTY) to $90 from $96 and keeps a Neutral rating on the shares.
Revvity price target raised to $120 from $115 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Revvity (RVTY) to $120 from $115 and keeps a Buy rating on the shares. The firm said commentary on
Revvity Earnings Call Transcript: Q1 2026
Q1 2026 delivered strong organic growth and margin outperformance, with robust innovation and a strategic China immunodiagnostics divestiture set to enhance growth and margins. Updated 2026 guidance reflects higher margins, focused capital allocation, and continued operational efficiency.
Revvity reports Q1 adjusted EPS $1.06, consensus $1.02
Reports Q1 revenue $711M, consensus $704.18M. “We performed well in the first quarter, with organic growth and adjusted EPS exceeding our expectations, reflecting strong execution from our teams acros...
Revvity sees FY26 adjusted EPS $5.20-$5.30, consensus $5.40
Sees FY26 revenue $2.81-$2.84, consensus $2.98B.
Revvity Announces Financial Results for the First Quarter of 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing op...
Revvity price target lowered to $125 from $129 at Baird
Baird lowered the firm’s price target on Revvity (RVTY) to $125 from $129 and keeps an Outperform rating on the shares. The firm updated its model ahead of Q1 results.
Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on Augus...
Revvity Transcript: AGM 2026
The meeting featured board elections, auditor ratification, and approval of executive compensation, all passing with strong majorities. A bylaw amendment for special meetings was adopted, while a shareholder proposal on executive stock retention was rejected.
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: BofA Securities 2026 Health Care Conference Wednesday, May 13, 2026 ...
Revvity downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Luke Sergott downgraded Revvity (RVTY) to Equal Weight from Overweight with a price target of $95, down from $118. The firm sees margin risk heading into the company’s
Revvity to Hold Earnings Call on Tuesday, May 5, 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2026 financial results prior to market open on Tuesday, May 5, 2026. The Company wil...
Revvity unveils Signals BioDesign offering
Revvity (RVTY) announced that its Revvity Signals Software business is launching Signals BioDesign, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for b...
Revvity unveils Signals BioDesign offering
Revvity (RVTY) announced that its Revvity Signals Software business is launching Signals BioDesign, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for b...
Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business is launching Signals BioDesignTM, a cloud-native molecular cloning solution that stream...
Revvity price target lowered to $108 from $118 at Evercore ISI
Evercore ISI lowered the firm’s price target on Revvity (RVTY) to $108 from $118 and keeps an Outperform rating on the shares as part of the firm’s medical technology and
Revvity price target lowered to $96 from $105 at JPMorgan
JPMorgan lowered the firm’s price target on Revvity (RVTY) to $96 from $105 and keeps a Neutral rating on the shares. The firm updated models in the life science tools
Revvity upgraded to Hold from Sell at Nephron Research
Nephron Research upgraded Revvity (RVTY) to Hold from Sell with a $90 price target
Revvity Transcript: Barclays 28th Annual Global Healthcare Conference
The Signals platform is expanding with AI-driven launches like BioDesign, LabGistics, and Xynthetica, aiming to accelerate research and shift to a consumption-based revenue model. Growth is expected in both software and reagents, with conservative guidance reflecting policy risks, especially in China.
Revvity Transcript: TD Cowen 46th Annual Health Care Conference
Strong Q4 results and robust execution set the stage for 2026, with cost measures driving margin expansion and continued growth in diagnostics, software, and reproductive health. Signals software and new product launches are key to doubling revenue in five years.
Revvity Transcript: 47th Annual Raymond James Institutional Investor Conference
The company has transformed into a focused life sciences and diagnostics leader, emphasizing innovation in software, reagents, and strategic partnerships. AI is expected to drive demand, while operational rigor supports margin expansion and strong cash flow. Guidance for 2026 is conservative, with upside potential if markets recover.
Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026
WALTHAM, Mass.--(BUSINESS WIRE)-- #LifeSciences--Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high...